Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Maxime Barakat"'
Autor:
Giulia Morsica, Emanuela Messina, Sabrina Bagaglio, Laura Galli, Riccardo Lolatto, Michela Sampaolo, Maxime Barakat, Robert J. Israel, Antonella Castagna, Nicola Clementi
Publikováno v:
Microorganisms, Vol 12, Iss 6, p 1146 (2024)
The emergence of new SARS-CoV-2 variants can affect vaccine efficacy, laboratory diagnosis and the therapies already available, triggering interest in the search for antiviral agents for SARS-CoV-2 infections. Ribavirin (RBV) is a broad-spectrum anti
Externí odkaz:
https://doaj.org/article/93685f03fd2a40d99090936833aafeba
Ribavirin aerosol in hospitalized adults with respiratory distress and COVID‐19: An open‐label trial
Autor:
Garyfallia Poulakou, Maxime Barakat, Robert J. Israel, Marcelo R. Bacci, Virazole Collaborator Group for COVID‐19 Respiratory Distress
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 1, Pp 165-174 (2023)
Abstract There is an unmet medical need for effective treatments for hospitalized patients with coronavirus disease 2019 (COVID‐19). Ribavirin is a broad‐spectrum antiviral with demonstrated in vitro activity against multiple viruses, including s
Externí odkaz:
https://doaj.org/article/a4938741f24445cdab5a318478add0d3
Autor:
Ronald Vender, MD, Irina Turchin, MD, Perla Lansang, MD, Vimal H. Prajapati, MD, Mark Legault, PhD, Maxime Barakat, MD, PhD, MBA, Jensen Yeung, MD
Publikováno v:
JAAD International, Vol 8, Iss , Pp 60-63 (2022)
Externí odkaz:
https://doaj.org/article/a53ddb810c5f4625922358a67799b58b
Autor:
Peter Couroux, Alexandre Brkovic, Jason L. Vittitow, Robert J. Israel, Chinna Pamidi, Jignesh Patel, Maxime Barakat
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2159-2171 (2022)
Abstract Ribavirin is an inosine monophosphate dehydrogenase inhibitor. Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses. However, current treatment is long (12–18 h per day, 3–
Externí odkaz:
https://doaj.org/article/64286b44217a485795376ac88fad47fa
Publikováno v:
EClinicalMedicine, Vol 49, Iss , Pp 101436- (2022)
Summary: Background: Extended-release (ER) naltrexone/bupropion (NB) was associated with greater weight loss than placebo in four randomized, 56-week trials. The association of NB with longer-term maintenance of weight loss remains unknown. Methods:
Externí odkaz:
https://doaj.org/article/66cb47f4296c4029bb5933dbe59383ec
Publikováno v:
Procedia Structural Integrity. 44:528-535
Autor:
Ferah Özçelik, Sevda Aydın Kurna, Burak Şeker, Mutlu Acar, Maxime Barakat, Hatice Elvin Yıldız, Ömür Ö. Uçakhan, Emine Sibel Öncü, Zerrin Tuncer, Ali Rıza Cenk Çelebi, Ebru Toker, Yonca A. Akova, Zeynep Özbek, Sibel Kocabeyoglu, Ferda Ciftci, Emrullah Taşındı, Deniz Kaya
Publikováno v:
Ophthalmology and Therapy
Introduction To evaluate patient satisfaction with samfilcon A contact lenses (CLs) in intensive digital device users with myopia and to compare patient satisfaction with samfilcon A lenses to prior experience with senofilcon A or lotrafilcon B CLs.
Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial
Autor:
Garyfallia, Poulakou, Maxime, Barakat, Robert J, Israel, Marcelo R, Bacci, Ioannis, Xynogalas
Publikováno v:
Clinical and translational scienceREFERENCES.
There is an unmet medical need for effective treatments for hospitalized patients with coronavirus disease 2019 (COVID-19). Ribavirin is a broad-spectrum antiviral with demonstrated in vitro activity against multiple viruses, including severe acute r
Autor:
Maxime Barakat, Marie Razanakolona, Emanuela Messina, Andrea Andolina, Matteo Chiurlo, Robert J Israel, Antonella Castagna, Anna Danise, Giulio Ferrari
Publikováno v:
Infectious Diseases and Therapy
Ribavirin is an inosine monophosphate dehydrogenase inhibitor with demonstrated activity against coronaviruses, including SARS-CoV-2. Five hospitalized patients with COVID-19 (confirmed by positive tests for SARS-CoV-2) received treatment with ribavi
Autor:
Sean Wharton, Errol Gould, Peter Yin, Fernando Camacho, Elham Kamran, Melonie Burrows, Jessica Blavignac, Maxime Barakat, Rebecca A. G. Christensen
Publikováno v:
International Journal of Obesity (2005)
Background Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occ